In 2020, Roche acquired this orally bioavailable drug candidate capable of crossing the blood‒brain barrier, which was discovered by Inflazome UK Ltd. Phase 1 interventional studies on the safety, efficacy, PD and PK of this molecule were completed in cryopyrin-associated periodic syndrome patients in 2020 (NCT04015076). Here, NLRP3 is linked to Parkinson disease.